Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: A case-control study

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 2, 1999, Pages 145-153

  Sanduleanu, S ^a   Stridsberg, M ^c   Jonkers, D ^a   Hameeteman, W ^a   Biemond, I ^b   Lundqvist, G ^c   Lamers, C ^b   Stockbrugger R W ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; BLOOD LEVEL; CASE CONTROL STUDY; CONTROLLED STUDY; DYSPEPSIA; FEMALE; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STOMACH ACID;

ADULT; AGED; ANTI-ULCER AGENTS; CASE-CONTROL STUDIES; CHROMOGRANIN A; CHROMOGRANINS; CROSS-SECTIONAL STUDIES; DYSPEPSIA; FEMALE; GASTRIC ACID; GASTRINS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE;

EID: 0005924729     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00466.x     Document Type: Article

References (55)

1. Larsson H, Carlsson E, Mattson H, et al. Plasma gastrin and enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986; 90: 391-9.
2. Hakanson R, Böttcher G, Sundler F, et al. Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach. Digestion 1986; 35(Suppl. 1): 42-55.
3. Creutzfeldt W. The achlorhydria-carcinoid sequence. Role of Gastrin. Digestion 1988; 39: 61-79.
4. Hakanson R, Sundler F. Proposed mechanism of induction of gastric carcinoids: The gastrin hypothesis. Eur J Clin Invest 1990; 20(Suppl. 1): 65-71.
5. Hakanson R, Chen D, Tielemans Y, et al. ECL cells: biology and pathobiology. Digestion 1994; 55(Suppl. 3): 38-45.
6. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35: 42-55.
7. Havu N, Mattsson H, Ekman L, et al. Enterochromaffin cell carcinoids in rat gastric mucosa following long-term administration of ranitidine. Digestion 1990; 45: 189-95.
8. Tielemans Y, Hakanson R, Sundler F, et al. Proliferation of enterochromaffin-like cells in omeprazole treated hypergastrinernic rats. Gastroenterology 1989; 96: 723-9.
9. Solcia E, Rindi G, Havu N, et al. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol 1989; 24(Suppl. 66): 129-137.
10. Creutzfeldt W, Lamberts R. et al. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. Digestion 1992; 51(Suppl. 1): 76-81.
11. Solcia E, Capella C, Fiocca, et al. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 1990; 14: 503-13.
12. Lchy T, Cadiot G, Mignon M, et al. Influence of multiple endocrine neoplasia type-1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992; 33: 1275-9.
13. Lehy T, Mignon M. Cadiot G, et al. Gastric endocrine cell behaviour in ZollingerEllison patients upon long-term potent antisecretory treatment. Gastroenterology 1989; 96: 1029-40.
14. Carney JA, Go VWL, Fairbanks, et al. The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy. Ann Intern Med 1983; 99: 761-6.
15. Bordi C, Pilato F, Carfagna G, et al. Argyrophil cell hyperplasia of flandic mucosa in patients with chronic atrophic gastritis. Digestion 1986; 35 (Suppl. 1): 130-43.
16. Borch K, Renvall H, Liedberg G, et al. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985; 88: 638-48.
17. Solcia E, Fiocca R, Villani L, et al. Morphology and natural history of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis. Scand J Gastroenterol 1991; 26(Suppl. 180): 146-59.
18. Chandrasekharappa S, Guru S, Manickarn P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276(5311): 404-7.
19. Solcia E, Rindi G, Fiocca R, et al. Distinct patterns of chronic gastritis associated with carcinoid, neuroendocrine carcinoma or ordinary cancer and their role in tumorigenesis. Yale J Biol Med 1992; 65: 793-804.
20. Bordi C, D'Adda T, Azzoni C, et al. Hypergastrinemia and Gastric Enterochromaffin like Cells. Am J Surg Pathol 1995; 19(Suppl. 1): S8-S19.
21. Lamberts R, Creutzfeldt W, Stockmann F, et al. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988; 39: 126-35.
22. Lamberts R, Creutzfeldt W, Strüber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth and gastritis. Gastroenterology 1993; 104: 1356-70.
23. Klinkenberg-Knol E, Festen H, Jansen J. et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Int Med 1994; 121(3): 161-7.
24. Penston JG, Dixon JS, Selway SAM, et al. Gastric histology and plasma gastrin response to a meal in patients with duodenal ulcer disease after five years treatment with ranitidine. Aliment Pharmacol Ther 1990; 4: 381-92.
25. Kuipers EJ. Uyterlinde AM, Pena S, et al. Increase of Helicobacter-pylori-associated corpus gastritis during acid-suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90(9): 1401-6.
26. Kuipers EJ, Lundell L, Klinkenberg-Knol E, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
27. Solcia E, Villani L, Luinetti O, et al. Proton pump inhibitors, enterochromaffin-like cell growth and Helicobacter pylori gastritis. Aliment Pharmacol Ther 1993; 7(Suppl. 1): 25-8.
28. El-Nujumi A, Williams C, McColl KEL, et al. Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment. Gut 1998; 42: 159-65.
29. Eissele P, Brunner G, Simon B, et al. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-17.
30. Waldum BL, Brenna E, Kleveland PM, et al. Review article: the use of gastric acid inhibitory drugs-physiological and pathophysiological considerations. Aliment Pharmacol Ther 1993; 7: 589-96.
31. Waldum M, Brenna E, Kleveland PM, et al. Gastrin-physiological and pathophysiological role: clinical consequences. Dig Dis 1995; 13: 25-38.
32. Waldum BL, Haugen OA, Isaksen R, et al. Enterochromaffin-like cells in the diffuse but not the intestinal type of gastric carcinomas. Scand J Gastroenterol 1991; 26(Suppl. 180): 165-9.
33. Modlin I, Lawton G, Miu K, et al. Pathophysiology of the fundic enterochromaffin-like (ECL) cell and gastric carcinoid tumours. Ann R Coll Surg Engl 1996; 78: 133-8.
34. O'Connor D, Deftos LS. Secretion of chromogranin A by peptide producing endocrine cell. N Engl J Med 1986; 314: 1145-51.
35. Stridsberg M, Hellman U, Wilander E, et al. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours. Development of a specific radioimmuno-assay for chromogranin A and its fragments. J Endocrinol 1993; 139: 329-37.
36. Stridsberg M, Oberg K, Li Q, et al. Measurement of chromogranin A, chromogranin B (secretogranin 1), chromogranin C (secretogranin 11) and pancreastatin in plasma and urine of patients with carcinoid tumours. J Endocrinol 1995; 144: 49-59.
37. Fahrenkamp AG, Wibbeke Q, Winde G, et al. Immunohistochemical distribution of chromogranins A and B and secretogranin 11 in neuroendocrine tumours of the gastrointestinal tract. Virchows Arch 1995; 426: 361-7.
38. Oberg K. Neuroendocrine gastrointestinal tumors - Review. Ann Oncol 1996; 7: 453-563.
39. Stabile B, Howard T, Pasaro E, et al. Source of plasma chromogranin A elevation in gastrinoma patients. Arch Surg 1990; 125: 451-3.
40. Syversen U, Mignon M, Bonfils S, et al. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncologica 1993; 32(2): 161-5.
41. Borch K, Stridsberg M, Burman P, et al. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997; 32: 198-202.
42. Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after orneprazole treatment. Gut 1996; 39: 649-53.
43. Houben P, Lundqvist G, Biemond I, et al. Twenty-four-hour intragastric pH, basal and meal-stimulated serum gastrin, and plasma chromogranin A after short-term acid inhibition. Gastroenterology 1997; 112(4): A152.
44. Bonten M, Galliard C, Stockbrügger R, et al. Assessment of gastric acidity in intensive care patients: intermittent pH registration cannot replace continuous pH monitoring. Intensive Care Med 1996; 22(3): 220-5.
45. Jansen J, Lamers C. Effect of changes in serum calcium on secretin-stimulated serum gastrin in patients with Zollinger-Ellison syndrome. Gastroenterol 1982; 83: 173-8.
46. Mc Cloy RF, Arnold I, Bardhan KD, et al. Pathophysiological effects of long-term acid suppression in man. Digestive Dis Sci 1995; 40(2): 96S-120S.
47. Leth R, Olbe L, Haglund U, et al. The pentagastrin-induced gastric acid response in humans. Scand J Gastroenterol 1988; 23: 224-48.
48. Waldum H, Sandvik A, Brenna E, et al. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut 1991; 32: 698-701.
49. Hakanson R, Sundler F. Do histamine-storing cells in the gastric mucosa mediate the acid-stimulating action of gastrin? Handbook Exp Pharm 1991; 97: 325-46.
50. Yogeshar D. Hyperplastic Proliferations of the ECL cells. Yale J Biol Med 1992; 65: 805-25.
51. Driman DK, Wright C, Tougas G, et al. Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Digestive Dis Sci 1996; 41(10): 2039-47.
52. Lind T, Cederberg C, Forssell H, et al. Relationship between reduction of acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol 1988; 23: 1259-66.
53. Jansen J, Klinkenberg-Knol E, Meuwissen S, et al. Effects of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990; 99: 621-8.
54. Hendy GN, Bevan S, Mattei MG, et al. Chromogranin A. Clin Invest Med 1995; 18: 47-65.
55. Lewis JJ, Mon MJ, Adrian TE, et al. Pancreastatin: a novel peptide inhibitor of parietal cell secretion. Surgery 1988; 104: 1031-6.